The impact of the herpetic eye disease studies on the management of herpes simplex virus ocular infections.
Herpes simplex virus (HSV) is a leading cause of chronic infectious ocular disease in the United States. The morbidity from recurrent herpetic episodes is high, and the resultant corneal scarring may require penetrating keratoplasty for visual rehabilitation. Effective treatments for acute episodes of HSV have been verified by early Herpetic Eye Disease Study (HEDS) trials. The recent HEDS trial on the efficacy of oral acyclovir as prophylaxis against recurrent stromal keratitis represents the first report of a treatment likely to reduce long-term scarring from herpetic disease. This article reviews all the HEDS trials and the implications of their findings for the management of patients with ocular HSV.
Sudesh
S
S
Cornea Service, Wills Eye Hospital, Philadelphia, PA 19107, USA.
Laibson
P R
PR
D000212:Acyclovir / Q000627:therapeutic use; D000284:Administration, Oral; D000998:Antiviral Agents / Q000627:therapeutic use*; D003319:Corneal Stroma / Q000187:drug effects* / Q000821:virology; D006801:Humans; D007500:Iritis / Q000188:drug therapy / Q000821:virology; D016849:Keratitis, Herpetic / Q000188:drug therapy* / Q000821:virology; D011239:Prednisolone / Q000031:analogs & derivatives / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D012008:Recurrence; D014271:Trifluridine / Q000627:therapeutic use
D000998:Antiviral Agents; C009022:prednisolone phosphate; D011239:Prednisolone; D014271:Trifluridine; D000212:Acyclovir